Skip to Content


Active substance(s): BETIATIDE

View full screen / Print PDF » Download PDF ⇩
DRN 4334

Technescan MAG3 United Kingdom & Northern Ireland

DRN 4334

Page 1 of 2

Package leafiet: Information for the user

TechneScan® MAG3
powder for solution for injection
Active substance: Betiatide
Read all of this leaflet carefully before you start using this medicine.
- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor or pharmacist.
- If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
In this leaflet:
1. What TechneScan® MAG3 is and what it is used for
2. Before you use TechneScan®MAG3
3. How to use TechneScan® MAG3
4. Possible side effects
5. How to store TechneScan®MAG3
6. Further information


What TechneScan®MAG3 is and what
it is used for

This medicine is for diagnostic use only.
TechneScan® MAG3 is used through a scan to examine the:
• kidneys,
• urine output and
• bladder.
This medicine is a powder. When mixed by qualified people, with a solution
of the radioactive substance, sodium pertechnetate (99mTc) it forms
Technetium [99n1TcJ tiatide. When injected into the body it collects in certain
organs such as, the kidneys.

Pregnancy and breast·feeding
• Pregnancy
Tell your doctor if you are pregnant or think you cou ld be . Your
doctor will only administer TechneScan®MAG3 during pregnancy
if it is absolutely necessary, as it could harm the unborn child .
• Breast-feeding
Tell your doctor if you are breast-feeding as he may delay
treatment until breast-feedi ng is finished. He may also ask you
to stop breast-feeding for 8 hours and discard this milk, until
the radioactivity is no longer in your body.
Ask your doctor or pharmacist for advice before taking any

The radioactive substance can be photographed from outside the body, Driving and using machines
using special cameras which take a scan. This scan shows the distribution TechneScan® MAG3 is unlikely to impair the ability to drive and
of radioactivity within the organ and body. This also gives the doctor operate machinery.
valuable information about the structure and function of that organ.



Before you use TechneScan® MAG3

Do not use TechneScan® MAG3
if you have/a re
• allergic (hypersensitive) to betiatide or any of the other ingredients

Take special care with TechneScan® MAG3
This medicine does involve treatment with radioactivity. Your doctor
will only give [O)you this medicine if the benefit outweighs the risk .
Tech neScan® MAG3 is given [OJby specialists, who will take
responsibility for any necessary precautions . [OJ
Your doctor will inform you if you need to take any special
precautions after using this medicine. Contact your doctor if you
have any questions .

How to use TechneScan® MAG3

TechneScan®MAG3 will always be used in a hospital or similar setting. It
will only be administered to you by qualified people trained to safe
handle radioactive material.
Your doctor will decide the TechneScan ®MAG3 amount to be used.
The dose administered will depends on the procedure you are
having and other factors such as your age.
The lowest dose possible will be used to produce adequate X- ray

The usual dose is:
Approximate doses for adults and the elderly are:
• 37-185 MBq, injected into a vein
MBq is the unit used to measure radioactivity, and defines the
activity of a quantity of radioactive material.

Children under 18 years
Lower doses are used for children according to their body surface

How many scans

Using other medicines
Please tell your doctor or pharmacist if you are taking or have
recently taken any other medicines, including medicines obtained
without a prescription.
TechneScan ® MAG3 is not known to influence or be influenced by
other medicines commonly used during the investigations mentioned

One injection is usually sufficient.
Drink and urinate as much as possible before and after
treatment. This will prevent active substance gathering in the

If you use more TechneScan® MAG3 than you should
It is unlikely that overdose will occur as this medicine is given under
control by a doctor. However, if this happens you will receive appropriate
treatment from your doctor.
If you have any further questions on the use of this product, ask your

043340068YS07a .doc 1 15 CON 433 4 UK SPC 17 1020 12 1 15 CON 4334 UK Pll 17 1020 12.

1 111111_r~1111 III

DRN 4334


Technescan MAG3 United Kingdom & Northern Ireland

Possible side effects

Like all medicines, TechneScan0 MAG3 can cause side effects, although
not everybody gets them.
Side effects can occur with the following frequencies:
rare, occurs in 1 to 10 per 10,000 users
• mild allergic reactions, with signs such as hives, swelling of the eyelids ,
itching, nausea or headache
Your hospital staff will treat these reactions, if they occur.
Frequency unknown , from the data available
• minor fainting episodes
If any of the side effects gets serious, or if you notice any side effects not
listed in th is leaflet, please tell your doctor or pharmacist.


How to store TechneScan®MAG3

Do not use TechneScan0 MAG3 after the expiry date stated on the label.
Hospital staff will ensure correct storage temperature, between 2-8°C
as stated on the label.


Further information

What TechneScan®MAG3 contains
• The active substance is betiatide.
Each vial con tai ns 1 mg beti atide.
• The other ingredients are: disodium tartrate, tin(lI)chloride and

What TechneScan®MAG3 looks like and contents of the pack
TechneScan0 MAG3 is packaged in 10 ml type 1 Ph.Eur glass vials closed
with a butyl rubber stopper and sealed with an aluminium crimp cap. It is
supplied in one pack that contains 5 vials.

Marketing Authorisation Holder and Manufacturer
• Marketing Authorisation Holder
Mallinckrodt UI 4500 Parkway , Whiteley, Fareham
Hampshire, P015 7NY
United Kingdom
Tel: +44(0)1329224477, Fax: +44(0)1329224442
PL 41744/0018
• Manufacturer
Mallinckrodt Medical BV, Westerduinweg 3
1755 LE Petten , The Netherlands

This leaflet was last approved in 10/2012.

04334006BYS07 • .doc 1 15 CON 4334 UK SPC 17102012 1 15 CON 4334 UK PI L 17102012.




Page 2 of 2

Expand view ⇕

Source: Medicines and Healthcare Products Regulatory Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.